Closing the antidepressant efficacy gap between clinical trials and real patient populations

References

• World Health Organization. Preamble to the Constitution of the World Health Organization as adopted by the International Health Conference, New York, 19–22 June, 1946; signed on 22 July 1946 by the representatives of 61 States (Official Records of the World Health Organization, no. 2, p. 100) and entered into force on 7 April 1948.
   Google Scholar
• Depression Guideline Panel. Clinical Practice Guideline, No. 5. Depression in Primary Care, Vol 2 AHCPR Publication No. 93-0551 Treatment of Major Depression. 1993; Rockville, MD: Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research.
   Google Scholar
• Baldwin DS, Anderson IM, Nutt DJ, et al. British Association for Psychopharmacology. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2005; 19(6)567–96
   PubMed Web of Science ®Google Scholar
• Sánchez C. The pharmacology of citalopram enantiomers: the antagonism by R-citalopram on the effect of S-citalopram. Basic Clin Pharmacol Toxicol 2006;99:91–5.
   PubMed Web of Science ®Google Scholar
• Kasper S, Spadone C, Verpillat P, Angst J. Onset of action of escitalopram compared with other antidepressants: results of a pooled analysis. Int Clin Psychopharmacol 2006; 21(2)105–10
   Google Scholar
• Kennedy SH, Andersen HF, Lam RW. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: A meta-analysis. J Psychiatry Neurosci 2006; 31(2)122–31
   Google Scholar
• Thase ME, Haight BR, Richard N, et al. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry 2005; 66(8)974–81
   PubMed Web of Science ®Google Scholar
• Pampallona S, Bollini P, Tibaldi G, Kupelnick B, Munizza C. Combined pharmacotherapy and psychological treatment for depression: a systematic review. Arch Gen Psychiatry 2004; 61(7)714–9
   PubMed Web of Science ®Google Scholar
• Paykel ES. Depression: major problem for public health. Epidemiol Psichiatr Soc 2006; 15(1)4–10
   PubMedGoogle Scholar
• Reiss-Brennan B, Briot P, Cannon W, James B. Mental health integration: rethinking practitioner roles in the treatment of depression: the specialist, primary care physicians, and the practice nurse. Ethn Dis 2006; 16(2 Suppl 3)S3-37–43
   Google Scholar
• Joo JH, Solano FX, Mulsant BH, Reynolds CF, Lenze EJ. Predictors of adequacy of depression management in the primary care setting. Psychiatr Serv 2005; 56(12)1524–8
   Google Scholar
• Schulberg HC, Block MR, Madonia MJ, et al. Treating major depression in primary care practice. Eight-month clinical outcomes. Arch Gen Psychiatry 1996; 53(10)913–9
   Google Scholar
• Simon G, Von Korff M, Wagner E, Barlow W. Patterns of antidepressant use in community practice. Gen Hosp Psychiatry 1995; 53: 399–408
   Google Scholar
• Lin EH, Katon WJ, VonKorff M, et al. Relapse of depression in primary care. Rate and clinical predictors. Arch Fam Med 1998; 7(5)443–9
   PubMedGoogle Scholar
• Martin RM, May M, Gunnell D. Did intense adverse media publicity impact on prescribing of paroxetine and the notification of suspected adverse drug reactions? Analysis of routine databases, 2001–2004. Br J Clin Pharmacol 2006; 61(2)224–8
   Google Scholar
• Simon GE, Savarino J, Operskalski B, Wang PS. Suicide risk during antidepressant treatment. Am J Psychiatry 2006; 163(1)41–7
   PubMed Web of Science ®Google Scholar
• ChildLine Report 2006 [ http://www.childline.org.uk/SharpriseinsuicidecallswarnsChildLine.asp].
   Google Scholar
• Paykel ES, Hart D, Priest RG. Changes in public attitudes to depression during the Defeat Depression Campaign. Br J Psychiatry 1998; 173: 519–22
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Rush AJ, Wisniewski SR, et al. STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006; 163(1)28–40
   PubMed Web of Science ®Google Scholar
• Von Korff M, Goldberg D. Improving outcomes in depression. Br Med J 2001; 323(7319)948–9
   Google Scholar
• Kessler RC, Sonnega A, Bromet E, Hughes M, Nelson CB. Posttraumatic stress disorder in the National Comorbidity Survey. Arch Gen Psychiatry 1995; 52(12)1048–60
   PubMed Web of Science ®Google Scholar
• APA. Diagnostic and statistical manual of mental disorders. 4th ed. Text revision. Washington, DC: American Psychiatric Association; 2000.
   Google Scholar
• Brawman-Mintzer O, Lydiard RB, Emmanuel N, et al. Psychiatric comorbidity in patients with generalized anxiety disorder. Am J Psychiatry 1993; 150(8)1216–8
   Google Scholar
• Rasmussen SA, Eisen JL. The epidemiology and differential diagnosis of obsessive compulsive disorder. J Clin Psychiatry 1992; 53(Suppl)4–10
   PubMedGoogle Scholar
• Dunner DL. Management of anxiety disorders: the added challenge of comorbidity. Depress Anxiety 2001; 13(2)57–71
   PubMed Web of Science ®Google Scholar
• Kasper S. Anxiety disorders: under-recognised and insufficiently treated. Int J Psychiatry Clin Pract 2006; 10(Suppl 1)3–9
   Google Scholar
• Coplan JD, Gorman JM. Treatment of anxiety disorder in patients with mood disorders. J Clin Psychiatry 1990;51(Suppl):9–13; discussion 14–7.
   PubMedGoogle Scholar
• Hirschfeld RM. The comorbidity of major depression and anxiety disorders: recognition and management in primary care. Prim Care Companion J Clin Psychiatry 2001; 3(6)244–54
   PubMedGoogle Scholar
• Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51(1)8–19
   PubMed Web of Science ®Google Scholar
• Wade A. Poster presented at DURG/British Society for Pharmacoepidemiology, 2005.
   Google Scholar
• Katon W, Rutter C, Ludman EJ, et al. A randomized trial of relapse prevention of depression in primary care. Arch Gen Psychiatry 2001; 58(3)241–7
   Web of Science ®Google Scholar
• Katon W, Russo J, Von Korff M, et al. Long-term effects of a collaborative care intervention in persistently depressed primary care patients. J Gen Intern Med 2002; 17(10)741–8
   PubMed Web of Science ®Google Scholar
• Katon W, Von Korff M, Lin E, et al. Stepped collaborative care for primary care patients with persistent symptoms of depression: a randomized trial. Arch Gen Psychiatry 1999; 56: 1109–15
   PubMed Web of Science ®Google Scholar
• Valenstein M, Vijan S, Zeber JE, Boehm K, Buttar A. The cost-utility of screening for depression in primary care. Ann Intern Med 2001; 134(5)345–60
   PubMed Web of Science ®Google Scholar
• Wade A, Despiegel N, Heldbo Reines E. Escitalopram in the long-term treatment of major depressive disorder. Ann Clin Psychiatry 2006; 18(2)83–9
   Google Scholar
• Terry CM, Kohlenberg RJ. Review: long term psychotherapy in combination with antidepressants increases compliance and response rates in people with depression. Evid Based Ment Health 2005; 8(1)12
   Google Scholar
• Rufer M, Hand I, Alsleben H, et al. Long-term course and outcome of obsessive-compulsive patients after cognitive-behavioral therapy in combination with either fluvoxamine or placebo: a 7-year follow-up of a randomized double-blind trial. Eur Arch Psychiatry Clin Neurosci 2005; 255(2)121–8
   PubMed Web of Science ®Google Scholar